Incyte Corporation (INCY)
Debt-to-assets ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 18,080 | 17,862 | 17,647 |
Total assets | US$ in thousands | 6,782,110 | 6,388,240 | 6,208,260 | 5,797,620 | 5,840,980 | 5,510,210 | 5,319,040 | 5,054,220 | 4,933,350 | 4,198,830 | 3,904,620 | 3,661,440 | 3,560,920 | 3,307,430 | 3,212,320 | 2,752,420 | 3,426,750 | 3,214,820 | 2,947,630 | 2,754,160 |
Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
December 31, 2023 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $6,782,110K
= 0.00
Incyte Corp.'s debt-to-assets ratio has remained consistently low, hovering around 0.01 for the past eight quarters. This indicates that the company has been successful in managing its debt levels relative to its total assets. A low debt-to-assets ratio suggests that the company relies more on equity financing rather than debt financing, which can be seen as a positive indicator of financial health and stability. Overall, Incyte Corp. appears to have a strong balance sheet with a conservative approach to debt management.
Peer comparison
Dec 31, 2023
Company name
Symbol
Debt-to-assets ratio
Incyte Corporation
INCY
0.00
Arrowhead Pharmaceuticals Inc
ARWR
0.00
Charles River Laboratories
CRL
0.00
Exelixis Inc
EXEL
0.00
IQVIA Holdings Inc
IQV
0.49
Medpace Holdings Inc
MEDP
0.00